International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Diabetic Nephropathy: Pathogenesis, Clinical Features, and Emerging Therapeutic Strategies

Gayathri Paturi[1], Arghadeep Sarkar[2], Dr. Bandi Veda Theja[3], Harshini Raja[4], Karothu Rohini[5], Raja Shekar Perusomula[*]

[1,2]Cognitive Science Research Initiative (CSRI) Lab, Department of Pharmacology, Vishnu Institute of Pharmaceutical Education & Research (VIPER), Hyderabad - 502313.
[3]Duty Medical Officer, Sree Ramadevi Multi Super Specialty Hospital, Tirupathi – 517501.
[4]Pharmaceutical Engineering, BV Raju Institute of Technology, Hyderabad- 502313.
[5]Assistant Professor, Department of Pharmacology, Avanthi Institute of Pharmaceutical Sciences, Vizianagaram – 531162.
[6]Professor, Cognitive Science Research Initiative (CSRI) Lab, Department of Pharmacology, Vishnu Institute of Pharmaceutical Education & Research (VIPER), Naraspur, 502313

ABSTRACT
Diabetic nephropathy (DN), also referred to as diabetic kidney disease (DKD), is a serious microvascular complication of diabetes mellitus and a leading cause of end-stage renal disease (ESRD) worldwide. It is marked by persistent albuminuria, a progressive decline in glomerular filtration rate (GFR), and elevated blood pressure. With the increasing global prevalence of diabetes, DN presents a major public health concern. Its pathogenesis involves hyperglycemia-induced metabolic disturbances, oxidative stress, inflammation, and fibrosis. Hemodynamic alterations, including intraglomerular hypertension and activation of the renin-angiotensin-aldosterone system (RAAS), further contribute to renal damage. Histological changes include mesangial expansion, thickening of the glomerular basement membrane, glomerulosclerosis, and tubulointerstitial fibrosis. Clinically, DN advances through five stages, from hyperfiltration to ESRD. Prognosis is influenced by glycemic control, blood pressure, genetic factors, and comorbidities. Diagnosis relies on the urinary albumin-to-creatinine ratio and estimated GFR. Management includes controlling blood glucose and blood pressure, lipid regulation, dietary changes, and RAAS inhibitors. Emerging treatments, such as SGLT2 inhibitors, finerenone, and anti-fibrotic agents, show promise. DN is linked to serious complications, especially cardiovascular disease, which remains the primary cause of death in affected patients.

KEYWORDS: Diabetic nephropathy, End-stage renal disease, Hyperglycemia, RAAS, SGLT2 inhibitors.

INTRODUCTION
Diabetic nephropathy (DN), also referred to as diabetic kidney disease (DKD), is one of the most serious microvascular complications of diabetes mellitus[1]. It is the leading cause of end-stage renal disease (ESRD) globally and significantly contributes to morbidity and mortality among diabetic patients. Characterized by persistent albuminuria, declining glomerular filtration rate (GFR), and increased

arterial blood pressure, DN develops in both type 1 and type 2 diabetes mellitus[2]. With the global rise in diabetes prevalence, DN has become a growing public health concern, necessitating a deeper understanding of its pathophysiology and the development of more effective therapeutic strategies[3].



Fig no.1: Difference between Normal kidney & Chronic Kidney Disease

EPIDEMIOLOGY AND RISK FACTORS

Globally, more than 500 million individuals are affected by diabetes mellitus, and approximately 30–40% of these individuals eventually develop diabetic nephropathy. DN accounts for nearly 40% of cases of ESRD in developed nations, including the United States, Japan, and various countries in Europe[4]. In developing countries, where healthcare access and glycemic control are often suboptimal, the burden may be even higher. Several risk factors have been identified in the progression of DN. These include poor glycemic control, long-standing diabetes, hypertension, genetic predisposition, dyslipidemia, obesity, smoking, and male gender[5]. Importantly, not all diabetic individuals develop nephropathy, highlighting the role of genetic and environmental modifiers in disease pathogenesis.



Fig no.2: Renal changes in type 1 diabetes mellitus

PATHOPHYSIOLOGY

The pathogenesis of DN is complex and multifactorial, involving hemodynamic changes, metabolic disturbances, oxidative stress, inflammation, and fibrosis. Hyperglycemia is the principal initiating factor, triggering a cascade of events that ultimately damage the glomeruli and tubulointerstitial compartments of the kidney.

Hyperglycemia and Metabolic Disturbances Persistent hyperglycemia leads to the formation of advanced glycation end products (AGEs), which bind to receptors on mesangial and endothelial cells, activating intracellular signaling pathways that result in increased production of pro-inflammatory cytokines, transforming growth factor-beta (TGF-β), and extracellular matrix proteins. These events contribute to mesangial expansion and glomerular basement membrane thickening- hallmarks of DN[6]. Furthermore, hyperglycemia stimulates the polyol pathway, leading to intracellular accumulation of sorbitol and subsequent oxidative stress. The hexosamine pathway is also activated, which can alter gene expression and promote fibrosis. Collectively, these metabolic abnormalities disrupt renal structure and function.

Hemodynamic Alterations Renal hemodynamic changes play a critical role in the initiation and progression of DN. Early in the disease, intraglomerular hypertension and hyperfiltration are observed due to afferent arteriolar vasodilation and efferent arteriolar constriction, mediated by increased angiotensin II and other vasoactive substances. This increased pressure damages the glomerular capillary walls and promotes proteinuria. The renin-angiotensin-aldosterone system (RAAS) is upregulated in DN, contributing to vasoconstriction, sodium retention, and fibrosis. RAAS activation also promotes inflammatory and fibrotic responses in the kidney, exacerbating injury[7].



Fig no.3: Pathophysiology of Diabetic Nephropathy

Oxidative Stress and Inflammation Reactive oxygen species (ROS) are generated in excess in the diabetic milieu. Mitochondrial dysfunction, activation of NADPH oxidase, and reduction of antioxidant defenses all contribute to oxidative stress in renal cells. ROS not only damage cellular structures but also activate nuclear factor-kappa B (NF-κB), a transcription factor that induces the expression of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-1 (MCP-1)[8]. Inflammatory cell infiltration is commonly observed in the kidneys of patients with DN. Inflammatory cytokines further stimulate fibroblast activation and extracellular matrix deposition, promoting tubulointerstitial fibrosis and glomerulosclerosis.

Fibrosis TGF-β is a key mediator of renal fibrosis. It stimulates the synthesis of collagen and fibronectin, leading to extracellular matrix accumulation. In advanced stages of DN, glomerular and tubular fibrosis contributes to irreversible loss of kidney function[9]. Other profibrotic factors include connective tissue growth factor (CTGF), angiotensin II, and endothelin-1.

CLINICAL STAGES OR PROGNOSIS OF DIABETIC NEPHROPATHY

1. Disease Progression DN progresses through five clinical stages, as described by Mogensen[10]:

Stage 1	Hyperfiltration	GFR is elevated and kidneys may be enlarged. No clinical symptoms are present
Stage 2	Silent stage	Structural damage begins; microalbuminuria may be absent or intermittent.
Stage 3	Microalbuminuria	Also called incipient nephropathy. Urinary albumin excretion ranges from 30 to 300 mg/day.
Stage 4	Macroalbuminuria or overt nephropathy	Albuminuria exceeds 300 mg/day. Hypertension is common and GFR begins to decline.
Stage 5	End-stage renal disease	Severe reduction in GFR (<15 mL/min/1.73 m^2), requiring dialysis or kidney transplantation.

2. Factors Affecting Prognosis[11]

Glycemic Control: Poor control accelerates nephropathy progression.
Blood Pressure: Hypertension worsens DN; control improves outcomes.
Genetic Susceptibility: Family history can influence disease severity.
Comorbid Conditions: Cardiovascular disease, obesity, and dyslipidemia increase risks.
Age and Gender: Elderly and male patients tend to have a faster decline in renal function.

3. Survival Rates

Patients with diabetic nephropathy have significantly lower survival rates than diabetic patients without nephropathy. The mortality rate increases sharply once patients reach ESRD, largely due to cardiovascular complications. Dialysis or transplantation can extend survival, but overall prognosis remains poor compared to non-diabetic ESRD patients[12].

DIAGNOSIS

The diagnosis of DN is primarily clinical, based on the presence of persistent albuminuria, reduced GFR, and the history of diabetes. Urinary albumin-to-creatinine ratio (UACR) is a commonly used measure for detecting albuminuria. Microalbuminuria is the earliest marker, while macroalbuminuria indicates progression. Serum creatinine and estimated GFR (eGFR) are used to assess renal function. Renal

biopsy is not routinely performed but may be indicated in atypical presentations or to rule out non-diabetic kidney diseases[13].

MANAGEMENT STRATEGIES OF DN

The goals of DN management include delaying disease progression, controlling blood pressure, reducing albuminuria, and preventing cardiovascular complications.

1. Glycemic Control

Tight glycemic control is essential for slowing the onset and progression of DN. Studies such as the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) have demonstrated that maintaining glycated hemoglobin (HbA1c) below 7% significantly reduces the risk of microvascular complications[14]. Newer antidiabetic agents like SGLT2 inhibitors (e.g., empagliflozin, canagliflozin) and GLP-1 receptor agonists (e.g., liraglutide) have shown renoprotective effects independent of glucose lowering.

2. Blood Pressure Control

Hypertension accelerates the progression of DN. The target blood pressure is typically less than 130/80 mmHg. RAAS inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are first-line therapies due to their dual effect of lowering blood pressure and reducing albuminuria[15]. Mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone) are also used in resistant cases but require careful monitoring due to the risk of hyperkalemia.

3. Lipid Management

Dyslipidemia is commonly associated with DN and contributes to cardiovascular disease. Statins are widely used to lower LDL cholesterol and provide cardiovascular protection. Some evidence suggests that statins may also slow renal disease progression, although the effect is modest[16].

4. Diet and Lifestyle Modifications

Lifestyle changes are critical in managing DN. A diet low in sodium and protein can reduce glomerular hyperfiltration and proteinuria[17]. Regular physical activity, smoking cessation, and weight management are essential components of comprehensive care[18].

5. Emerging Therapies[19]

Recent research has focused on targeting inflammation, oxidative stress, and fibrosis in DN. Several novel agents are under investigation:

SGLT2 Inhibitors: Beyond glucose control, these drugs reduce intraglomerular pressure and inflammation.

Finerenone: A non-steroidal mineralocorticoid receptor antagonist that has shown promise in reducing kidney and cardiovascular outcomes in DN patients[20].

Endothelin Receptor Antagonists: These reduce proteinuria and slow progression, though fluid retention remains a concern.

Anti-fibrotic agents: Molecules targeting TGF-β and CTGF are under preclinical and clinical evaluation.

Gene therapy, stem cell therapy, and use of microRNAs represent future avenues for intervention, although these are still in experimental stages[21].



Fig no.4: Management strategies of DN

COMPLICATIONS OF DIABETIC NEPHROPATHY

1. **Cardiovascular Disease** Most Common Cause of Death: DN significantly raises the risk of coronary artery disease, myocardial infarction, and stroke[22].
1. Mechanism: Chronic inflammation, endothelial dysfunction, and arterial stiffness contribute to cardiovascular events. Heart Failure: Fluid overload from renal dysfunction leads to volume expansion and congestive heart failure[19].
2. **End-Stage Renal Disease (ESRD)** ESRD requires renal replacement therapy (RRT) such as dialysis or kidney transplantation. DN is the primary cause of ESRD in many countries, including the US and India[23].
3. **Hypertension** Both a cause and consequence of DN, it worsens glomerular damage and accelerates progression. Often difficult to control in advanced stages, requiring multiple antihypertensive agents.
4. **Electrolyte Imbalance** Hyperkalemia: Common in advanced DN due to reduced renal potassium excretion. Metabolic Acidosis: Impaired acid excretion leads to systemic acidosis, muscle wasting, and bone demineralization[24].
5. **Anemia** caused by decreased erythropoietin production by damaged kidneys. Leads to fatigue, decreased quality of life[25], and further cardiovascular strain.
6. **Bone Mineral Disorders** Renal Osteodystrophy: Imbalance of calcium, phosphate, and parathyroid hormone (PTH) results in bone demineralization[26]. Vascular Calcification: Due to calcium-phosphate imbalance, increasing the risk of cardiovascular events.
7. **Malnutrition and Cachexia** Loss of appetite, proteinuria-induced protein loss, and inflammation can lead to malnutrition[27] and muscle wasting in advanced DN.

8. **Increased Infection Risk** Immunosuppression due to uremia and poor glycemic control heightens the risk of infections[28] like urinary tract infections, pneumonia, and sepsis.
9. **Neurological Complications** Uremic encephalopathy, peripheral neuropathy, and cognitive dysfunction can occur in the late stages[29].

SUMMARY

Diabetic nephropathy (DN) remains a leading cause of end-stage renal disease (ESRD) worldwide, significantly impacting the quality of life and survival of individuals with diabetes. Its pathogenesis is complex, involving hyperglycemia-induced metabolic changes, hemodynamic alterations, oxidative stress, inflammation, and progressive fibrosis. The disease progresses through defined clinical stages, ultimately resulting in irreversible renal failure. Timely diagnosis through early detection of microalbuminuria and assessment of glomerular filtration rate is critical for effective intervention.

Comprehensive management strategies, including optimal glycemic and blood pressure control, lipid regulation, dietary and lifestyle modifications, and the use of renoprotective agents such as RAAS inhibitors and SGLT2 inhibitors, are essential in slowing disease progression and reducing complications. Emerging therapies targeting novel pathways such as fibrosis and inflammation offer hope for improved outcomes. Despite these advancements, DN continues to pose a significant public health challenge due to its associated complications, particularly cardiovascular disease. Therefore, continued research into the underlying mechanisms and development of innovative therapies is imperative. Early intervention and a multidisciplinary approach remain key to improving prognosis and preventing progression to ESRD.

REFERENCES

1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045.
2. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1)\:S147-S160.
3. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
4. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514-23.
5. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care. 2014 Oct;37(10):2864-83.
6. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-88.
7. Ruiz-Ortega M, Rodríguez-Vita J, Sánchez-López E, Carvajal G, Egido J. TGF-β signaling in vascular fibrosis. Cardiovasc Res. 2007;74(2):196-206.
8. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008 Mar;19(3):433-42.
9. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684-96.
10. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356-60.
11. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis. 2014 Jan;63(1 Suppl)\:A7.

12. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care. 2005 Jan;28(1):164-76.
13. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020 Oct;98(4S)\:S1–S115.
14. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346(15):1145-51.
15. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the UKPDS 64. Kidney Int. 2003 Jan;63(1):225-32.
16. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
17. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct;383(15):1436–46.
18. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy. N Engl J Med. 2001 Sep;345(12):870-8.
19. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020 Dec;383(23):2219–29.
20. Rossing K, Jacobsen P, Rossing N, Jensen BR, Parving H. Renal structure and function in patients with type 2 diabetes: a longitudinal study. Diabetes. 2004;53(3):1098-104.
21. Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, et al. Protective effect of GLP-1 receptor agonist against kidney injury in mice with type 2 diabetes. Am J Physiol Renal Physiol. 2007;293(4)\:F1254-62.
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.
23. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.
24. Sharma K. Obesity, oxidative stress, and fibrosis in chronic kidney disease. Kidney Int Suppl. 2014;4(1):113–7.
25. Wu H, Kong L, Cheng Y, Zhang Z, Wang Y, Wang C. Role of inflammation and oxidative stress in diabetic kidney disease. Chin Med J (Engl). 2020;133(12):1611-9.
26. Ahn SY, Park CW. The role of lipotoxicity in diabetic nephropathy. Kidney Res Clin Pract. 2013;32(1):9–15.
27. Chatla H, Hema G, Paturi G, Gopavarapu CK, Perusomula RS. Physiological and Pathological Hypertrophic Cardiomyopathy.
28. Bhalla V, Daouk A, Jani V. Diagnostic approach to diabetic nephropathy in 2023. Curr Diab Rep. 2023;23(1):22-32.
29. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care. 2002;25(5):859–64.